VivoSeq
Oncology

Penile Cancer

22

Pipeline Programs↗

6

Active Trials↗

16

Companies Involved↗

Penile Cancer is an emerging landscape with 22 programs across 16 companies. The most active players are Imclone, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Eastern Cooperative Oncology Group. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

15/100

Mech. Concentration

23/100

Completion Rate

83/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Imclone

1 program

Phase 1M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 2A

Avyxa

1 program

Phase 2Incyte logo

Incyte

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

22programs
Monoclonal antibody1150%
Small molecule1045%
Antibody–drug conjugate15%

Modality classified for 100% of 22 pipeline programs.

Analysis

Trial Status

12

clinical trials

Completed5 · 42%
Not yet recruiting3 · 25%
Recruiting2 · 17%
Terminated1 · 8%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer
Recruiting·SSun Yat-sen University·Phase 2·NCT06415318·25 enrolled
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT06353906·27 enrolled
A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based Chemotherapy
Active, not recruiting·UUniversity Health Network, Toronto·Phase 2·NCT03391479·25 enrolled
Single-Arm Trial of QL1706, Lenvatinib, and Nab-Paclitaxel for Advanced Refractory Penile Cancer
Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07384416·47 enrolled
A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER
Not yet recruiting·HHospital Israelita Albert Einstein·Phase 2·NCT07101822·42 enrolled
Neoadjuvant Therapy With EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) for Penile Squamous Cell Carcinoma With Penile Preservation Difficulty or Regional Lymph Node Metastasis: A Single-Arm, Phase II Clinical Trial
Not yet recruiting·—·Phase 2·NCT07518979·60 enrolled
PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study
Completed·TThe Netherlands Cancer Institute·Phase 2·NCT03686332·32 enrolled
Image Guided Penile Cancer Surgery
Completed·UUniversity Medical Center Groningen·Phase 1·NCT05376202·11 enrolled
Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00066391
TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer
Completed·SSun Yat-sen University·Phase 2·NCT04475016·29 enrolled
Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer
Completed·LLatin American Cooperative Oncology Group·Phase 2·NCT04224740·37 enrolled
S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)
Terminated·SWOG Cancer Research Network·Phase 2·NCT00058448·1 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)